Kailera reports Q1 2026 results, initiates Phase 3 ribupatide trials

Clinical-stage biotech Kailera advanced its obesity pipeline with five late-stage trial initiations and positive data from partner programs, reporting cash runway into mid-2028. The company's ribupatide franchise and diverse drug candidates position it competitively in the obesity treatment market.